Extensive clinical investigation has shown that ketanserin is an effective first‐line antihypertensive agent with particular advantages in older patients. It has a favorable hemodynamic profile and seems devoid of serious side‐effects. Clinical studies in various diseases indicate a gradual improvement of the microcirculation, which is compatible with selective serotonin S2‐antagonism. Ketanserin has a favorable influence on several cardiovascular risk factors. Preliminary data suggest that it has vascular protective effects in patients with atherosclerosis.
No takes yet. Share an insight, caveat, or question.
Symoens et al. (1986) studied this question.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: